Anhil Parenterals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 17-07-2024
- Paid Up Capital ₹ 4.51 M
as on 17-07-2024
- Company Age 33 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.61 Cr
as on 17-07-2024
- Satisfied Charges ₹ 1.35 Cr
as on 17-07-2024
- Revenue -1.54%
(FY 2023)
- Profit 43.98%
(FY 2023)
- Ebitda 22.41%
(FY 2023)
- Net Worth 28.92%
(FY 2023)
- Total Assets -6.09%
(FY 2023)
About Anhil Parenterals
The Corporate was formerly known as Sensitive Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.51 M.
The company currently has active open charges totaling ₹7.61 Cr. The company has closed loans amounting to ₹1.35 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pramodbhai Patel, Parth Patel, and Sanket Patel serve as directors at the Company.
- CIN/LLPIN
U24231GJ1991PTC015847
- Company No.
015847
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jun 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Patan, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Anhil Parenterals Private Limited offer?
Anhil Parenterals Private Limited offers a wide range of products and services, including Dentist Tools, Equipment & Supplies, Dental Instruments.
Who are the key members and board of directors at Anhil Parenterals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramodbhai Patel  | Director | 11-Sep-1996 | Current |
| Parth Patel | Director | 21-Mar-2019 | Current |
| Sanket Patel | Director | 21-Mar-2019 | Current |
Financial Performance of Anhil Parenterals.
Anhil Parenterals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.54% decrease. The company also saw a substantial improvement in profitability, with a 43.98% increase in profit. The company's net worth Soared by an impressive increase of 28.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anhil Parenterals?
In 2023, Anhil Parenterals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 06 Nov 2023 | ₹6.23 Cr | Open |
Sidbi Creation Date: 16 Dec 2021 | ₹1.38 Cr | Open |
Sidbi Creation Date: 25 Jun 2020 | ₹5.00 M | Satisfied |
How Many Employees Work at Anhil Parenterals?
Unlock and access historical data on people associated with Anhil Parenterals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anhil Parenterals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anhil Parenterals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
